1561 / 1631
RT improves survival in patients with testicular DLBCL
Ho et al, Leuk Lymphoma 2017
•
Retrospective analysis of 120 Stage I–IV testicular
DLBCL patients treated 1964- 2015 at MDACC
•
Aim: assess benefits of prophylactic contralateral
testicular RT and prophylactic CNS therapy
•
Testicular RT: 70%; median dose 30.6 Gy (range, 24–
40 Gy), at a median 1.8 Gy per fraction
•
CNS profylaxis: 61%
(intrathecal or high dose MTX)